Skip to main content
ANAPTYSBIO, INC logo

ANAPTYSBIO, INC — Investor Relations & Filings

Ticker · ANAB ISIN · US0327241065 LEI · 529900HH4WQT03IG1A12 US Professional, scientific and technical activities
Open in API
Filings indexed 636 across all filing types
Latest filing 2015-12-23 Capital/Financing Update
Country US United States of America
Listing US ANAB

About ANAPTYSBIO, INC

https://www.anaptysbio.com/

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the discovery and development of innovative immunology therapeutics. The company specializes in advancing immune cell-modulating antibodies designed to treat autoimmune and inflammatory diseases. Its therapeutic candidates target key pathways in the immune system to address significant unmet medical needs for various patient populations.

Recent filings

Filing Released Lang Actions
S-1/A
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC, dated December 23, 2015. It is a registration statement under the Securities Act of 1933 for an initial public offering (IPO) of common stock by AnaptysBio, Inc. The text includes detailed information about the offering, company overview, risk factors, management discussion, financial data, and other disclosures typical of an S-1 filing. Form S-1 is a registration statement used for securities offerings and is not an annual report, earnings release, or other financial report. It is a capital markets filing related to the company's financing activities and public offering of shares. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed substantive information, not just an announcement or certification, supporting a high confidence level.
2015-12-23 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a letter from the company's legal counsel to the SEC Division of Corporation Finance regarding a Registration Statement on Form S-1 filed by AnaptysBio, Inc. It discusses valuation considerations related to recent equity awards and the anticipated price range for the company's initial public offering (IPO). The letter references the Registration Statement and the Preliminary Prospectus, and it is clearly a supplemental correspondence addressing SEC staff comments. The document does not contain financial statements or a full report but is a regulatory correspondence related to the IPO registration process. It is not an Annual Report, Earnings Release, or any other financial report type. It is also not a report publication announcement but a regulatory filing responding to SEC comments. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (13,891 characters) and content support this classification with high confidence.
2015-09-24 English
Regulatory Filings 2015
Regulatory Filings Classification · 100% confidence The document is a letter from legal counsel to the SEC responding to comments on a draft Registration Statement on Form S-1 for AnaptysBio, Inc. It discusses amendments to the draft registration statement, including details about a proposed reverse stock split, regulatory risks, clinical development plans, and FDA approval processes. The document references the Form S-1 registration statement and amendments but does not contain financial statements or actual financial data. It is a correspondence related to a regulatory filing rather than the filing itself. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC correspondence and filings that do not fit other categories.
2015-09-09 English
S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated September 9, 2015, for AnaptysBio, Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes detailed information about the company, its business, management, risk factors, use of proceeds, and underwriting details. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript, audit report, or other types of filings. The S-1 is a capital markets filing related to the company's offering of securities to the public. According to the provided filing categories, the closest match is Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. Therefore, the document should be classified as CAP with high confidence.
2015-09-09 English
Regulatory Filings 2015
Regulatory Filings
2015-08-31 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a company (AnaptysBio, Inc.) to the U.S. Securities and Exchange Commission (SEC) staff regarding comments on a draft registration statement on Form S-1. The letter discusses revisions and clarifications made to the draft registration statement, which is a filing used for initial public offerings (IPOs) or other securities offerings. The presence of references to the Form S-1, confidential treatment requests, detailed disclosures about the company's business, strategy, risk factors, and offering details indicate this is part of the registration process for securities offerings. This type of document is a regulatory filing related to securities registration and is not itself a financial report, earnings release, or other types of filings listed. It is a correspondence with the SEC staff addressing comments on a draft registration statement. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2015-08-18 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.